Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemited
NCT07264673Phase 2Recruiting
- Sponsor
- Fondazione Ricerca Traslazionale
- Start
- Apr 2025
- Primary completion
- Oct 2027
- Modality
- Prophylactic Vaccines, Peptides, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of Tedopi in non-small cell lung cancer (NSCLC), sponsored by Fondazione Ricerca Traslazionale. Started Apr 2025; status: recruiting.
02
Drugs
Tedopi
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07264673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07264673.